News
CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...
On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...
Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...
5d
Dealbreaker on MSNSarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’
Financial analysts lambasted Sarepta executives for failing to disclose a drug-test fatality when the company announced a ...
1d
TipRanks on MSNEtsy, Celestica, Biogen, Sarepta, Macy’s: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($ETSY) ), ( ($CLS) ), ( ($BIIB) ), ( ($SRPT) ) and ( ($M) ). Here is a breakdown ...
The Dow Jones Industrial Average slipped on Friday (July 18) amid reports that US President Donald Trump is pushing for ...
Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results